img

Global Cancer Angiogenesis Inhibitors Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Cancer Angiogenesis Inhibitors Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Cancer Angiogenesis Inhibitors report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Cancer Angiogenesis Inhibitors market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Cancer and Interferon Alpha-2α are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Cancer Angiogenesis Inhibitors industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Cancer Angiogenesis Inhibitors key manufacturers include Intas Pharmaceuticals, Kyowa Hakko Kirin, Levolta Pharmaceuticals, Mabtech, Marsala Biotech, Neumedicines, Genentech, Five Prime Therapeutics and Fuji Film Kyowa Kirin Biologics, etc. Intas Pharmaceuticals, Kyowa Hakko Kirin, Levolta Pharmaceuticals are top 3 players and held % sales share in total in 2022.
Cancer Angiogenesis Inhibitors can be divided into VEGF Targeted Therapy, FGF Targeted Therapies, Oncogene Targeted Therapy and Matrix Degrading & Remodeling Targeted Therapy, etc. VEGF Targeted Therapy is the mainstream product in the market, accounting for % sales share globally in 2022.
Cancer Angiogenesis Inhibitors is widely used in various fields, such as Cancer, Interferon Alpha-2α and Ocular Neovascularization,, etc. Cancer provides greatest supports to the Cancer Angiogenesis Inhibitors industry development. In 2022, global % sales of Cancer Angiogenesis Inhibitors went into Cancer filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Cancer Angiogenesis Inhibitors market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Intas Pharmaceuticals
Kyowa Hakko Kirin
Levolta Pharmaceuticals
Mabtech
Marsala Biotech
Neumedicines
Genentech
Five Prime Therapeutics
Fuji Film Kyowa Kirin Biologics
Genexine
Hetero Drugs
ImClone Systems
Novartis
Segment by Type
VEGF Targeted Therapy
FGF Targeted Therapies
Oncogene Targeted Therapy
Matrix Degrading & Remodeling Targeted Therapy
Others

Segment by Application


Cancer
Interferon Alpha-2α
Ocular Neovascularization

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Cancer Angiogenesis Inhibitors market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Cancer Angiogenesis Inhibitors, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Cancer Angiogenesis Inhibitors industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Cancer Angiogenesis Inhibitors in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Cancer Angiogenesis Inhibitors introduction, etc. Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Cancer Angiogenesis Inhibitors market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.

Table of Content

1 Cancer Angiogenesis Inhibitors Market Overview
1.1 Cancer Angiogenesis Inhibitors Product Overview
1.2 Cancer Angiogenesis Inhibitors Market Segment by Type
1.2.1 VEGF Targeted Therapy
1.2.2 FGF Targeted Therapies
1.2.3 Oncogene Targeted Therapy
1.2.4 Matrix Degrading & Remodeling Targeted Therapy
1.2.5 Others
1.3 Global Cancer Angiogenesis Inhibitors Market Size by Type
1.3.1 Global Cancer Angiogenesis Inhibitors Market Size Overview by Type (2018-2034)
1.3.2 Global Cancer Angiogenesis Inhibitors Historic Market Size Review by Type (2018-2024)
1.3.3 Global Cancer Angiogenesis Inhibitors Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Cancer Angiogenesis Inhibitors Sales Breakdown by Type (2018-2024)
1.4.2 Europe Cancer Angiogenesis Inhibitors Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Cancer Angiogenesis Inhibitors Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Cancer Angiogenesis Inhibitors Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Cancer Angiogenesis Inhibitors Sales Breakdown by Type (2018-2024)
2 Global Cancer Angiogenesis Inhibitors Market Competition by Company
2.1 Global Top Players by Cancer Angiogenesis Inhibitors Sales (2018-2024)
2.2 Global Top Players by Cancer Angiogenesis Inhibitors Revenue (2018-2024)
2.3 Global Top Players by Cancer Angiogenesis Inhibitors Price (2018-2024)
2.4 Global Top Manufacturers Cancer Angiogenesis Inhibitors Manufacturing Base Distribution, Sales Area, Product Type
2.5 Cancer Angiogenesis Inhibitors Market Competitive Situation and Trends
2.5.1 Cancer Angiogenesis Inhibitors Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Cancer Angiogenesis Inhibitors Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cancer Angiogenesis Inhibitors as of 2022)
2.7 Date of Key Manufacturers Enter into Cancer Angiogenesis Inhibitors Market
2.8 Key Manufacturers Cancer Angiogenesis Inhibitors Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Cancer Angiogenesis Inhibitors Status and Outlook by Region
3.1 Global Cancer Angiogenesis Inhibitors Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Cancer Angiogenesis Inhibitors Historic Market Size by Region
3.2.1 Global Cancer Angiogenesis Inhibitors Sales in Volume by Region (2018-2024)
3.2.2 Global Cancer Angiogenesis Inhibitors Sales in Value by Region (2018-2024)
3.2.3 Global Cancer Angiogenesis Inhibitors Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Cancer Angiogenesis Inhibitors Forecasted Market Size by Region
3.3.1 Global Cancer Angiogenesis Inhibitors Sales in Volume by Region (2024-2034)
3.3.2 Global Cancer Angiogenesis Inhibitors Sales in Value by Region (2024-2034)
3.3.3 Global Cancer Angiogenesis Inhibitors Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Cancer Angiogenesis Inhibitors by Application
4.1 Cancer Angiogenesis Inhibitors Market Segment by Application
4.1.1 Cancer
4.1.2 Interferon Alpha-2α
4.1.3 Ocular Neovascularization
4.2 Global Cancer Angiogenesis Inhibitors Market Size by Application
4.2.1 Global Cancer Angiogenesis Inhibitors Market Size Overview by Application (2018-2034)
4.2.2 Global Cancer Angiogenesis Inhibitors Historic Market Size Review by Application (2018-2024)
4.2.3 Global Cancer Angiogenesis Inhibitors Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Cancer Angiogenesis Inhibitors Sales Breakdown by Application (2018-2024)
4.3.2 Europe Cancer Angiogenesis Inhibitors Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Cancer Angiogenesis Inhibitors Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Cancer Angiogenesis Inhibitors Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Cancer Angiogenesis Inhibitors Sales Breakdown by Application (2018-2024)
5 North America Cancer Angiogenesis Inhibitors by Country
5.1 North America Cancer Angiogenesis Inhibitors Historic Market Size by Country
5.1.1 North America Cancer Angiogenesis Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Cancer Angiogenesis Inhibitors Sales in Volume by Country (2018-2024)
5.1.3 North America Cancer Angiogenesis Inhibitors Sales in Value by Country (2018-2024)
5.2 North America Cancer Angiogenesis Inhibitors Forecasted Market Size by Country
5.2.1 North America Cancer Angiogenesis Inhibitors Sales in Volume by Country (2024-2034)
5.2.2 North America Cancer Angiogenesis Inhibitors Sales in Value by Country (2024-2034)
6 Europe Cancer Angiogenesis Inhibitors by Country
6.1 Europe Cancer Angiogenesis Inhibitors Historic Market Size by Country
6.1.1 Europe Cancer Angiogenesis Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Cancer Angiogenesis Inhibitors Sales in Volume by Country (2018-2024)
6.1.3 Europe Cancer Angiogenesis Inhibitors Sales in Value by Country (2018-2024)
6.2 Europe Cancer Angiogenesis Inhibitors Forecasted Market Size by Country
6.2.1 Europe Cancer Angiogenesis Inhibitors Sales in Volume by Country (2024-2034)
6.2.2 Europe Cancer Angiogenesis Inhibitors Sales in Value by Country (2024-2034)
7 Asia-Pacific Cancer Angiogenesis Inhibitors by Region
7.1 Asia-Pacific Cancer Angiogenesis Inhibitors Historic Market Size by Region
7.1.1 Asia-Pacific Cancer Angiogenesis Inhibitors Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Cancer Angiogenesis Inhibitors Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Cancer Angiogenesis Inhibitors Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Cancer Angiogenesis Inhibitors Forecasted Market Size by Region
7.2.1 Asia-Pacific Cancer Angiogenesis Inhibitors Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Cancer Angiogenesis Inhibitors Sales in Value by Region (2024-2034)
8 Latin America Cancer Angiogenesis Inhibitors by Country
8.1 Latin America Cancer Angiogenesis Inhibitors Historic Market Size by Country
8.1.1 Latin America Cancer Angiogenesis Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Cancer Angiogenesis Inhibitors Sales in Volume by Country (2018-2024)
8.1.3 Latin America Cancer Angiogenesis Inhibitors Sales in Value by Country (2018-2024)
8.2 Latin America Cancer Angiogenesis Inhibitors Forecasted Market Size by Country
8.2.1 Latin America Cancer Angiogenesis Inhibitors Sales in Volume by Country (2024-2034)
8.2.2 Latin America Cancer Angiogenesis Inhibitors Sales in Value by Country (2024-2034)
9 Middle East and Africa Cancer Angiogenesis Inhibitors by Country
9.1 Middle East and Africa Cancer Angiogenesis Inhibitors Historic Market Size by Country
9.1.1 Middle East and Africa Cancer Angiogenesis Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Cancer Angiogenesis Inhibitors Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Cancer Angiogenesis Inhibitors Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Cancer Angiogenesis Inhibitors Forecasted Market Size by Country
9.2.1 Middle East and Africa Cancer Angiogenesis Inhibitors Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Cancer Angiogenesis Inhibitors Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Intas Pharmaceuticals
10.1.1 Intas Pharmaceuticals Company Information
10.1.2 Intas Pharmaceuticals Introduction and Business Overview
10.1.3 Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Products Offered
10.1.5 Intas Pharmaceuticals Recent Development
10.2 Kyowa Hakko Kirin
10.2.1 Kyowa Hakko Kirin Company Information
10.2.2 Kyowa Hakko Kirin Introduction and Business Overview
10.2.3 Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Products Offered
10.2.5 Kyowa Hakko Kirin Recent Development
10.3 Levolta Pharmaceuticals
10.3.1 Levolta Pharmaceuticals Company Information
10.3.2 Levolta Pharmaceuticals Introduction and Business Overview
10.3.3 Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Products Offered
10.3.5 Levolta Pharmaceuticals Recent Development
10.4 Mabtech
10.4.1 Mabtech Company Information
10.4.2 Mabtech Introduction and Business Overview
10.4.3 Mabtech Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Mabtech Cancer Angiogenesis Inhibitors Products Offered
10.4.5 Mabtech Recent Development
10.5 Marsala Biotech
10.5.1 Marsala Biotech Company Information
10.5.2 Marsala Biotech Introduction and Business Overview
10.5.3 Marsala Biotech Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Marsala Biotech Cancer Angiogenesis Inhibitors Products Offered
10.5.5 Marsala Biotech Recent Development
10.6 Neumedicines
10.6.1 Neumedicines Company Information
10.6.2 Neumedicines Introduction and Business Overview
10.6.3 Neumedicines Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Neumedicines Cancer Angiogenesis Inhibitors Products Offered
10.6.5 Neumedicines Recent Development
10.7 Genentech
10.7.1 Genentech Company Information
10.7.2 Genentech Introduction and Business Overview
10.7.3 Genentech Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Genentech Cancer Angiogenesis Inhibitors Products Offered
10.7.5 Genentech Recent Development
10.8 Five Prime Therapeutics
10.8.1 Five Prime Therapeutics Company Information
10.8.2 Five Prime Therapeutics Introduction and Business Overview
10.8.3 Five Prime Therapeutics Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Five Prime Therapeutics Cancer Angiogenesis Inhibitors Products Offered
10.8.5 Five Prime Therapeutics Recent Development
10.9 Fuji Film Kyowa Kirin Biologics
10.9.1 Fuji Film Kyowa Kirin Biologics Company Information
10.9.2 Fuji Film Kyowa Kirin Biologics Introduction and Business Overview
10.9.3 Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Products Offered
10.9.5 Fuji Film Kyowa Kirin Biologics Recent Development
10.10 Genexine
10.10.1 Genexine Company Information
10.10.2 Genexine Introduction and Business Overview
10.10.3 Genexine Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Genexine Cancer Angiogenesis Inhibitors Products Offered
10.10.5 Genexine Recent Development
10.11 Hetero Drugs
10.11.1 Hetero Drugs Company Information
10.11.2 Hetero Drugs Introduction and Business Overview
10.11.3 Hetero Drugs Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.11.4 Hetero Drugs Cancer Angiogenesis Inhibitors Products Offered
10.11.5 Hetero Drugs Recent Development
10.12 ImClone Systems
10.12.1 ImClone Systems Company Information
10.12.2 ImClone Systems Introduction and Business Overview
10.12.3 ImClone Systems Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.12.4 ImClone Systems Cancer Angiogenesis Inhibitors Products Offered
10.12.5 ImClone Systems Recent Development
10.13 Novartis
10.13.1 Novartis Company Information
10.13.2 Novartis Introduction and Business Overview
10.13.3 Novartis Cancer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.13.4 Novartis Cancer Angiogenesis Inhibitors Products Offered
10.13.5 Novartis Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Cancer Angiogenesis Inhibitors Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Cancer Angiogenesis Inhibitors Industrial Chain Analysis
11.4 Cancer Angiogenesis Inhibitors Market Dynamics
11.4.1 Cancer Angiogenesis Inhibitors Industry Trends
11.4.2 Cancer Angiogenesis Inhibitors Market Drivers
11.4.3 Cancer Angiogenesis Inhibitors Market Challenges
11.4.4 Cancer Angiogenesis Inhibitors Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Cancer Angiogenesis Inhibitors Distributors
12.3 Cancer Angiogenesis Inhibitors Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of VEGF Targeted Therapy
Table 2. Major Company of FGF Targeted Therapies
Table 3. Major Company of Oncogene Targeted Therapy
Table 4. Major Company of Matrix Degrading & Remodeling Targeted Therapy
Table 5. Major Company of Others
Table 6. Global Cancer Angiogenesis Inhibitors Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Cancer Angiogenesis Inhibitors Sales by Type (2018-2024) & (K Pcs)
Table 8. Global Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Type (2018-2024)
Table 9. Global Cancer Angiogenesis Inhibitors Sales by Type (2018-2024) & (US& Million)
Table 10. Global Cancer Angiogenesis Inhibitors Market Share in Value by Type (2018-2024)
Table 11. Global Cancer Angiogenesis Inhibitors Price by Type (2018-2024) & (USD/Pcs)
Table 12. Global Cancer Angiogenesis Inhibitors Sales by Type (2024-2034) & (K Pcs)
Table 13. Global Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Type (2024-2034)
Table 14. Global Cancer Angiogenesis Inhibitors Sales by Type (2024-2034) & (US$ Million)
Table 15. Global Cancer Angiogenesis Inhibitors Sales Market Share in Value by Type (2024-2034)
Table 16. Global Cancer Angiogenesis Inhibitors Price by Type (2024-2034) & (USD/Pcs)
Table 17. North America Cancer Angiogenesis Inhibitors Sales by Type (2018-2024) & (K Pcs)
Table 18. North America Cancer Angiogenesis Inhibitors Sales by Type (2018-2024) & (US$ Million)
Table 19. Europe Cancer Angiogenesis Inhibitors Sales (K Pcs) by Type (2018-2024)
Table 20. Europe Cancer Angiogenesis Inhibitors Sales by Type (2018-2024) & (US$ Million)
Table 21. Asia-Pacific Cancer Angiogenesis Inhibitors Sales (K Pcs) by Type (2018-2024)
Table 22. Asia-Pacific Cancer Angiogenesis Inhibitors Sales by Type (2018-2024) & (US$ Million)
Table 23. Latin America Cancer Angiogenesis Inhibitors Sales (K Pcs) by Type (2018-2024)
Table 24. Latin America Cancer Angiogenesis Inhibitors Sales by Type (2018-2024) & (US$ Million)
Table 25. Middle East and Africa Cancer Angiogenesis Inhibitors Sales (K Pcs) by Type (2018-2024)
Table 26. Middle East and Africa Cancer Angiogenesis Inhibitors Sales by Type (2018-2024) & (US$ Million)
Table 27. Global Cancer Angiogenesis Inhibitors Sales by Company (2018-2024) & (K Pcs)
Table 28. Global Cancer Angiogenesis Inhibitors Sales Share by Company (2018-2024)
Table 29. Global Cancer Angiogenesis Inhibitors Revenue by Company (2018-2024) & (US$ Million)
Table 30. Global Cancer Angiogenesis Inhibitors Revenue Share by Company (2018-2024)
Table 31. Global Market Cancer Angiogenesis Inhibitors Price by Company (2018-2024) & (USD/Pcs)
Table 32. Global Cancer Angiogenesis Inhibitors Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 33. Global Cancer Angiogenesis Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 34. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cancer Angiogenesis Inhibitors as of 2022)
Table 35. Date of Key Manufacturers Enter into Cancer Angiogenesis Inhibitors Market
Table 36. Key Manufacturers Cancer Angiogenesis Inhibitors Product Type
Table 37. Mergers & Acquisitions, Expansion Plans
Table 38. Global Cancer Angiogenesis Inhibitors Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 39. Global Cancer Angiogenesis Inhibitors Sales by Region (2018-2024) & (K Pcs)
Table 40. Global Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Region (2018-2024)
Table 41. Global Cancer Angiogenesis Inhibitors Sales by Region (2018-2024) & (US$ Million)
Table 42. Global Cancer Angiogenesis Inhibitors Sales Market Share in Value by Region (2018-2024)
Table 43. Global Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 44. Global Cancer Angiogenesis Inhibitors Sales by Region (2024-2034) & (K Pcs)
Table 45. Global Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Region (2024-2034)
Table 46. Global Cancer Angiogenesis Inhibitors Sales by Region (2024-2034) & (US$ Million)
Table 47. Global Cancer Angiogenesis Inhibitors Sales Market Share in Value by Region (2024-2034)
Table 48. Global Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2024-2034)
Table 49. Global Cancer Angiogenesis Inhibitors Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 50. Global Cancer Angiogenesis Inhibitors Sales by Application (2018-2024) & (K Pcs)
Table 51. Global Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Application (2018-2024)
Table 52. Global Cancer Angiogenesis Inhibitors Sales by Application (2018-2024) & (US$ Million)
Table 53. Global Cancer Angiogenesis Inhibitors Sales Market Share in Value by Application (2018-2024)
Table 54. Global Cancer Angiogenesis Inhibitors Price by Application (2018-2024) & (USD/Pcs)
Table 55. Global Cancer Angiogenesis Inhibitors Sales by Application (2024-2034) & (K Pcs)
Table 56. Global Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Application (2024-2034)
Table 57. Global Cancer Angiogenesis Inhibitors Sales by Application (2024-2034) & (US$ Million)
Table 58. Global Cancer Angiogenesis Inhibitors Sales Market Share in Value by Application (2024-2034)
Table 59. Global Cancer Angiogenesis Inhibitors Price by Application (2024-2034) & (USD/Pcs)
Table 60. North America Cancer Angiogenesis Inhibitors Sales by Application (2018-2024) (K Pcs)
Table 61. North America Cancer Angiogenesis Inhibitors Sales by Application (2018-2024) & (US$ Million)
Table 62. Europe Cancer Angiogenesis Inhibitors Sales by Application (2018-2024) (K Pcs)
Table 63. Europe Cancer Angiogenesis Inhibitors Sales by Application (2018-2024) & (US$ Million)
Table 64. Asia-Pacific Cancer Angiogenesis Inhibitors Sales by Application (2018-2024) (K Pcs)
Table 65. Asia-Pacific Cancer Angiogenesis Inhibitors Sales by Application (2018-2024) & (US$ Million)
Table 66. Latin America Cancer Angiogenesis Inhibitors Sales by Application (2018-2024) (K Pcs)
Table 67. Latin America Cancer Angiogenesis Inhibitors Sales by Application (2018-2024) & (US$ Million)
Table 68. Middle East and Africa Cancer Angiogenesis Inhibitors Sales by Application (2018-2024) (K Pcs)
Table 69. Middle East and Africa Cancer Angiogenesis Inhibitors Sales by Application (2018-2024) & (US$ Million)
Table 70. North America Cancer Angiogenesis Inhibitors Sales by Country (2018-2024) & (K Pcs)
Table 71. North America Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Country (2018-2024)
Table 72. North America Cancer Angiogenesis Inhibitors Sales by Country (2018-2024) & (US$ Million)
Table 73. North America Cancer Angiogenesis Inhibitors Sales Market Share in Value by Country (2018-2024)
Table 74. North America Cancer Angiogenesis Inhibitors Sales by Country (2024-2034) & (K Pcs)
Table 75. North America Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Country (2024-2034)
Table 76. North America Cancer Angiogenesis Inhibitors Sales by Country (2024-2034) & (US$ Million)
Table 77. North America Cancer Angiogenesis Inhibitors Sales Market Share in Value by Country (2024-2034)
Table 78. Europe Cancer Angiogenesis Inhibitors Sales by Country (2018-2024) & (K Pcs)
Table 79. Europe Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Country (2018-2024)
Table 80. Europe Cancer Angiogenesis Inhibitors Sales by Country (2018-2024) & (US$ Million)
Table 81. Europe Cancer Angiogenesis Inhibitors Sales Market Share in Value by Country (2018-2024)
Table 82. Europe Cancer Angiogenesis Inhibitors Sales by Country (2024-2034) & (K Pcs)
Table 83. Europe Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Country (2024-2034)
Table 84. Europe Cancer Angiogenesis Inhibitors Sales by Country (2024-2034) & (US$ Million)
Table 85. Europe Cancer Angiogenesis Inhibitors Sales Market Share in Value by Country (2024-2034)
Table 86. Asia-Pacific Cancer Angiogenesis Inhibitors Sales by Region (2018-2024) & (K Pcs)
Table 87. Asia-Pacific Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Region (2018-2024)
Table 88. Asia-Pacific Cancer Angiogenesis Inhibitors Sales by Region (2018-2024) & (US$ Million)
Table 89. Asia-Pacific Cancer Angiogenesis Inhibitors Sales Market Share in Value by Region (2018-2024)
Table 90. Asia-Pacific Cancer Angiogenesis Inhibitors Sales by Region (2024-2034) & (K Pcs)
Table 91. Asia-Pacific Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Region (2024-2034)
Table 92. Asia-Pacific Cancer Angiogenesis Inhibitors Sales by Region (2024-2034) & (US$ Million)
Table 93. Asia-Pacific Cancer Angiogenesis Inhibitors Sales Market Share in Value by Region (2024-2034)
Table 94. Latin America Cancer Angiogenesis Inhibitors Sales by Country (2018-2024) & (K Pcs)
Table 95. Latin America Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Country (2018-2024)
Table 96. Latin America Cancer Angiogenesis Inhibitors Sales by Country (2018-2024) & (US$ Million)
Table 97. Latin America Cancer Angiogenesis Inhibitors Sales Market Share in Value by Country (2018-2024)
Table 98. Latin America Cancer Angiogenesis Inhibitors Sales by Country (2024-2034) & (K Pcs)
Table 99. Latin America Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Country (2024-2034)
Table 100. Latin America Cancer Angiogenesis Inhibitors Sales by Country (2024-2034) & (US$ Million)
Table 101. Latin America Cancer Angiogenesis Inhibitors Sales Market Share in Value by Country (2024-2034)
Table 102. Middle East and Africa Cancer Angiogenesis Inhibitors Sales by Country (2018-2024) & (K Pcs)
Table 103. Middle East and Africa Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Country (2018-2024)
Table 104. Middle East and Africa Cancer Angiogenesis Inhibitors Sales by Country (2018-2024) & (US$ Million)
Table 105. Middle East and Africa Cancer Angiogenesis Inhibitors Sales Market Share in Value by Country (2018-2024)
Table 106. Middle East and Africa Cancer Angiogenesis Inhibitors Sales by Country (2024-2034) & (K Pcs)
Table 107. Middle East and Africa Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Country (2024-2034)
Table 108. Middle East and Africa Cancer Angiogenesis Inhibitors Sales by Country (2024-2034) & (US$ Million)
Table 109. Middle East and Africa Cancer Angiogenesis Inhibitors Sales Market Share in Value by Country (2024-2034)
Table 110. Intas Pharmaceuticals Company Information
Table 111. Intas Pharmaceuticals Introduction and Business Overview
Table 112. Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 113. Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Product
Table 114. Intas Pharmaceuticals Recent Development
Table 115. Kyowa Hakko Kirin Company Information
Table 116. Kyowa Hakko Kirin Introduction and Business Overview
Table 117. Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 118. Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Product
Table 119. Kyowa Hakko Kirin Recent Development
Table 120. Levolta Pharmaceuticals Company Information
Table 121. Levolta Pharmaceuticals Introduction and Business Overview
Table 122. Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 123. Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Product
Table 124. Levolta Pharmaceuticals Recent Development
Table 125. Mabtech Company Information
Table 126. Mabtech Introduction and Business Overview
Table 127. Mabtech Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 128. Mabtech Cancer Angiogenesis Inhibitors Product
Table 129. Mabtech Recent Development
Table 130. Marsala Biotech Company Information
Table 131. Marsala Biotech Introduction and Business Overview
Table 132. Marsala Biotech Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 133. Marsala Biotech Cancer Angiogenesis Inhibitors Product
Table 134. Marsala Biotech Recent Development
Table 135. Neumedicines Company Information
Table 136. Neumedicines Introduction and Business Overview
Table 137. Neumedicines Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 138. Neumedicines Cancer Angiogenesis Inhibitors Product
Table 139. Neumedicines Recent Development
Table 140. Genentech Company Information
Table 141. Genentech Introduction and Business Overview
Table 142. Genentech Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 143. Genentech Cancer Angiogenesis Inhibitors Product
Table 144. Genentech Recent Development
Table 145. Five Prime Therapeutics Company Information
Table 146. Five Prime Therapeutics Introduction and Business Overview
Table 147. Five Prime Therapeutics Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 148. Five Prime Therapeutics Cancer Angiogenesis Inhibitors Product
Table 149. Five Prime Therapeutics Recent Development
Table 150. Fuji Film Kyowa Kirin Biologics Company Information
Table 151. Fuji Film Kyowa Kirin Biologics Introduction and Business Overview
Table 152. Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 153. Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Product
Table 154. Fuji Film Kyowa Kirin Biologics Recent Development
Table 155. Genexine Company Information
Table 156. Genexine Introduction and Business Overview
Table 157. Genexine Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 158. Genexine Cancer Angiogenesis Inhibitors Product
Table 159. Genexine Recent Development
Table 160. Hetero Drugs Company Information
Table 161. Hetero Drugs Introduction and Business Overview
Table 162. Hetero Drugs Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 163. Hetero Drugs Cancer Angiogenesis Inhibitors Product
Table 164. Hetero Drugs Recent Development
Table 165. ImClone Systems Company Information
Table 166. ImClone Systems Introduction and Business Overview
Table 167. ImClone Systems Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 168. ImClone Systems Cancer Angiogenesis Inhibitors Product
Table 169. ImClone Systems Recent Development
Table 170. Novartis Company Information
Table 171. Novartis Introduction and Business Overview
Table 172. Novartis Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 173. Novartis Cancer Angiogenesis Inhibitors Product
Table 174. Novartis Recent Development
Table 175. Key Raw Materials Lists
Table 176. Raw Materials Key Suppliers Lists
Table 177. Cancer Angiogenesis Inhibitors Market Trends
Table 178. Cancer Angiogenesis Inhibitors Market Drivers
Table 179. Cancer Angiogenesis Inhibitors Market Challenges
Table 180. Cancer Angiogenesis Inhibitors Market Restraints
Table 181. Cancer Angiogenesis Inhibitors Distributors List
Table 182. Cancer Angiogenesis Inhibitors Downstream Customers
Table 183. Research Programs/Design for This Report
Table 184. Key Data Information from Secondary Sources
Table 185. Key Data Information from Primary Sources
List of Figures
Figure 1. Cancer Angiogenesis Inhibitors Product Picture
Figure 2. Global Cancer Angiogenesis Inhibitors Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Cancer Angiogenesis Inhibitors Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Cancer Angiogenesis Inhibitors Sales Status and Outlook (2018-2034) & (K Pcs)
Figure 5. Product Picture of VEGF Targeted Therapy
Figure 6. Global VEGF Targeted Therapy Sales YoY Growth (2018-2034) & (K Pcs)
Figure 7. Product Picture of FGF Targeted Therapies
Figure 8. Global FGF Targeted Therapies Sales YoY Growth (2018-2034) & (K Pcs)
Figure 9. Product Picture of Oncogene Targeted Therapy
Figure 10. Global Oncogene Targeted Therapy Sales YoY Growth (2018-2034) & (K Pcs)
Figure 11. Product Picture of Matrix Degrading & Remodeling Targeted Therapy
Figure 12. Global Matrix Degrading & Remodeling Targeted Therapy Sales YoY Growth (2018-2034) & (K Pcs)
Figure 13. Product Picture of Others
Figure 14. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 15. Global Cancer Angiogenesis Inhibitors Sales by Type (2018-2034) & (US$ Million)
Figure 16. Global Cancer Angiogenesis Inhibitors Sales Market Share by Type in 2022 & 2034
Figure 17. North America Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Type in 2022
Figure 18. North America Cancer Angiogenesis Inhibitors Sales Market Share in Value by Type in 2022
Figure 19. Europe Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Type in 2022
Figure 20. Europe Cancer Angiogenesis Inhibitors Sales Market Share in Value by Type in 2022
Figure 21. Asia-Pacific Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Type in 2022
Figure 22. Asia-Pacific Cancer Angiogenesis Inhibitors Sales Market Share in Value by Type in 2022
Figure 23. Latin America Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Type in 2022
Figure 24. Latin America Cancer Angiogenesis Inhibitors Sales Market Share in Value by Type in 2022
Figure 25. Middle East and Africa Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Type in 2022
Figure 26. Middle East and Africa Cancer Angiogenesis Inhibitors Sales Market Share in Value by Type in 2022
Figure 27. The 5 and 10 Largest Manufacturers in the World: Market Share by Cancer Angiogenesis Inhibitors Sales in 2022
Figure 28. The 5 and 10 Largest Manufacturers in the World: Market Share by Cancer Angiogenesis Inhibitors Revenue in 2022
Figure 29. Cancer Angiogenesis Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 30. Product Picture of Cancer
Figure 31. Global Cancer Sales YoY Growth (2018-2034) & (K Pcs)
Figure 32. Product Picture of Interferon Alpha-2α
Figure 33. Global Interferon Alpha-2α Sales YoY Growth (2018-2034) & (K Pcs)
Figure 34. Product Picture of Ocular Neovascularization
Figure 35. Global Ocular Neovascularization Sales YoY Growth (2018-2034) & (K Pcs)
Figure 36. Global Cancer Angiogenesis Inhibitors Sales by Application (2018-2034) & (US$ Million)
Figure 37. Global Cancer Angiogenesis Inhibitors Sales Market Share by Application in 2022 & 2034
Figure 38. North America Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Application in 2022
Figure 39. North America Cancer Angiogenesis Inhibitors Sales Market Share in Value by Application in 2022
Figure 40. Europe Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Application in 2022
Figure 41. Europe Cancer Angiogenesis Inhibitors Sales Market Share in Value by Application in 2022
Figure 42. Asia-Pacific Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Application in 2022
Figure 43. Asia-Pacific Cancer Angiogenesis Inhibitors Sales Market Share in Value by Application in 2022
Figure 44. Latin America Cancer Angiogenesis Inhibitors Sales Market Share in Volume by Application in 2022
Figure 45. Latin America Cancer Angiogenesis Inhibitors Sales Market Share in Value by Application in 2022
Figure 46. Middle East and Africa Cancer Angiogenesis Inhibitors Sales Market Share in Value by Application in 2022
Figure 47. Key Raw Materials Price
Figure 48. Cancer Angiogenesis Inhibitors Manufacturing Cost Structure
Figure 49. Cancer Angiogenesis Inhibitors Industrial Chain Analysis
Figure 50. Channels of Distribution
Figure 51. Distributors Profiles
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries